Mylin Torres, MD, talks with Prof. Dr. med. Guido Hildebrandt about the secondary results of the INSEMA trial, which evaluated applied radiotherapy among patients undergoing breast-conserving surgery with or without axillary sentinel lymph node biopsy.

Marcela Mazo, MD, talks with Marjolein Smidt, MD, PhD, about the results of the Phase III BOOG 2013-08 trial, which indicate that sentinel lymph node biopsy may be safely omitted in some patients with early-stage breast cancer.

Saba Shaikh, MD, talks with Sonia Pernas, MD, PhD, about the results of the Phase II SUMIT-BC trial, which showed that the CDK7 inhibitor samuraciclib combined with fulvestrant demonstrated promising efficacy in ER+/HER2- locally advanced or metastatic breast cancer patients previously treated using an aromatase inhibitor with a CDK4/6 inhibitor.

Julie Nangia, MD, talks with Erika Hamilton, MD, about the results of the HER2CLIMB-05 study, a Phase III trial that demonstrated that adding tucatinib to first-line maintenance therapy with trastuzumab and pertuzumab delayed disease progression in patients with HER2-positive metastatic breast cancer, potentially extending time off chemotherapy.

Saba Shaikh, MD, talks with Komal Jhaveri, MD, about the results of the ASCENT-07 study, which demonstrated that patients with HR-positive, HER2-negative advanced breast cancers had similar progression-free survival whether they were treated with sacituzumab govitecan-hziy or standard-of-care chemotherapy as the first treatment after endocrine therapy.

Rahul Gosain, MD, of the Oncology Brothers, talks with Marleen Kok, MD, PhD, about how lobular carcinoma — which comprises 10-15% of all invasive breast cancers — differs from ductal carcinoma.

Rohit Gosain, MD, of the Oncology Brothers, talks with Kristy Brown, PhD, about the biological link between obesity and risk of breast cancer.

SABCS Program Director Kate Lathrop, MD, talks with Shom Goel, MBBS, PhD, about CDK4/6 inhibitors and emerging options to advance treatment for HR-positive, HER-negative metastatic breast cancer.

Rahul Gosain, MD, of the Oncology Brothers, talks with Virginia Borges, MD, about the increasing number of women under the age of 50 receiving a breast cancer diagnosis.

Rahul Gosain, MD, of the Oncology Brothers, talks with Mafalda Oliveira, MD, PhD, about the emerging class of drugs — including oral SERDs and PROTAC estrogen receptor degraders — and whether they are working better for patients.